Psych Congress 2026 Explores Emerging Psychedelic Medicine Trends

In a rapidly evolving landscape, Psych Congress 2026, held from September 15 to 19 in New Orleans, is set to bring together over 3,000 mental health professionals for an in-depth exploration of psychedelic medicine. The event aims to provide a comprehensive look at the emerging field, highlighting the potential for new therapies and their integration into mental health care.

The conference, which marks the 39th annual meeting of Psych Congress, is expected to feature five days of sessions, each aimed at addressing the complex issues surrounding psychedelic treatments. Attendees will have the opportunity to hear from patients, advocates, federal officials, and leading researchers, offering a multifaceted perspective on the future of psychiatry.

The event kicks off on September 15 with a keynote address from Marcus and Amber Capone, a Navy SEAL veteran and his wife. Their personal journey, which involved seeking treatment for PTSD and depression abroad, forms the backdrop of the conference. The Capones, co-founders of Veterans Exploring Treatment Solutions (VETS), will share their experiences and advocate for more research and clinical engagement.

Following the Capones, Matthew Zorn, Deputy General Counsel at the U.S. Department of Health and Human Services, will provide an update on federal policy. Zorn will address critical issues such as provider training, patient safety, and access, drawing from the context of the FDA's recent public hearing on potential future therapeutic uses of psychedelic drugs.

The timing of the FDA hearing, scheduled for September 14, underscores the urgency and rapid pace of change in the field. This makes the conference particularly timely, offering clinicians a rare opportunity to consider the implications of federal developments for their practice.

"HMP Global's Chief Learning Officer, Randy Robbin, emphasized the significance of the event, stating, 'There has never been a more innovative time in psychiatry, and the next two or three years could be among the most important in the field's history.'"

Interest in psychedelic medicine has surged, with a 2024 survey of U.S. healthcare professionals revealing that 80.9 percent believe psychedelics show promise for psychiatric disorders, up from 42.4 percent in 2016. However, despite this growing interest, knowledge and preparedness have not kept pace. A 2024 Scientific Reports survey found that only 20.6 percent of healthcare professionals could correctly answer knowledge questions about these compounds.

The clinical need is substantial. An estimated 30.9 percent of U.S. adults with major depressive disorder have treatment-resistant depression, underscoring the urgency of exploring new treatment options. However, the evidence for different psychedelic compounds varies widely, and none are currently FDA-approved for psychiatric indications.

Clinicians are increasingly being asked to address the rapidly evolving landscape, shaped by patient demand and advocacy. The conference aims to facilitate these conversations by bringing together diverse voices and expertise.

The program will cover various aspects of psychedelic therapy, including practical models for implementation, patient selection, treatment settings, and insurance coverage. Additional sessions will explore the broader implications for mental health care, including neuroplasticity and emerging approaches in anxiety disorders.

HMP Global, the organizer of Psych Congress, is also planning a new meeting in 2027 focused on psychedelic medicines and a new peer-reviewed journal. These initiatives aim to provide more platforms for clinicians, researchers, and other leaders to engage with the field and prepare for the future.

Psych Congress continues to be a leading platform for practical, case-based education in psychopharmacology, serving as a vital resource for mental health professionals across the country. The event's commitment to independent clinical content and its focus on patient experience make it a crucial forum for navigating the complex and rapidly evolving landscape of psychedelic medicine.